LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Accueil・Liste d'Actions・Arvinas Inc

Arvinas Inc

Fermé

SecteurSoins de santé

7.69 0.13

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

7.6899999999999995

Max

7.89

Chiffres clés
By Trading Economics
Revenu	9.8M -58M
Ventes	6.1M 16M
BPA	-0.9
Marge bénéficiaire	-369.231
Employés	246
EBITDA	4.4M -62M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+90.78% upside

Dividendes
By Dow Jones
Prochains Résultats	5 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-70M 554M
Ouverture précédente	7.56
Clôture précédente	7.69

Sentiment de l'Actualité

By Acuity

33%

67%

84 / 344 Classement par Healthcare

Arvinas Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

4 juin 2026, 21:51 UTC

Principaux Mouvements du Marché

Merlin Shares Rally After Defense Department's Design Review Wraps

4 juin 2026, 23:46 UTC

Market Talk

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 juin 2026, 23:44 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 juin 2026, 23:42 UTC

Acquisitions, Fusions, Rachats

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 juin 2026, 23:41 UTC

Acquisitions, Fusions, Rachats

Energy Resources of Australia to Enter Trading Halt

4 juin 2026, 23:34 UTC

Market Talk

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 juin 2026, 23:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 juin 2026, 23:31 UTC

Market Talk

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 juin 2026, 23:31 UTC

Market Talk

Global Equities Roundup: Market Talk

4 juin 2026, 23:08 UTC

Market Talk

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 juin 2026, 22:41 UTC

Market Talk

Australia Shares Set to Rise at the Open -- Market Talk

4 juin 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4 juin 2026, 20:44 UTC

Acquisitions, Fusions, Rachats

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 juin 2026, 20:16 UTC

Market Talk

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 juin 2026, 20:15 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 juin 2026, 19:46 UTC

Market Talk

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 juin 2026, 19:38 UTC

Market Talk

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 juin 2026, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 juin 2026, 18:47 UTC

Acquisitions, Fusions, Rachats

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 juin 2026, 18:38 UTC

Résultats

Money Quote: Tech Weakness in Context -- WSJ

4 juin 2026, 18:24 UTC

Résultats

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 juin 2026, 17:09 UTC

Market Talk

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 juin 2026, 16:58 UTC

Résultats

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 juin 2026, 16:46 UTC

Market Talk

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 juin 2026, 16:38 UTC

Résultats

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 juin 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

4 juin 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

4 juin 2026, 16:13 UTC

Market Talk

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 juin 2026, 16:11 UTC

Market Talk

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 juin 2026, 15:56 UTC

Market Talk

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Comparaison

Variation de prix

Arvinas Inc prévision

Objectif de Prix

By TipRanks

90.78% hausse

Prévisions sur 12 Mois

Moyen 14.69 USD 90.78%

Haut 24 USD

Bas 6 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

14 ratings

Achat

Maintien

Vente

Basé sur 14 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

84 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.